title: Acquired hemophilia as first manifestation of breast carcinoma in a man under long-term spironolactone therapy.
abstract: A 69-year-old man under long-term spironolactone therapy (16 years) was hospitalized with spontaneous hematoma on the trunk and extremities. Coagulation studies disclosed an acquired hemophilia that was successfully treated with human factor VIII for a few days and immunosuppressive agents for several months. Physical examination revealed bilateral gynecomastia and an upper left quadrant breast nodule. Complete staging was unremarkable. Complete left mastectomy was performed. Histopathology showed invasive ductal carcinoma, expressing positivity for estrogen and progesterone receptors. The acquired hemophilia was considered to be a paraneoplasic syndrome. The question of a linkage between long-term spironolactone therapy and breast carcinoma is discussed.
authors.affiliation: Service of Medicine A, Department of Internal Medicine, University Hospital, CHUV, BH10, CH-1011, Lausanne, Switzerland. olivier.lamy@chuv.hospvd.ch
authors.forename: Olivier
authors.initials: O
authors.lastname: Lamy
authors.forename: Hubert
authors.initials: H
authors.lastname: Elmiger
authors.forename: Maryse
authors.initials: M
authors.lastname: Fiche
authors.forename: Jean
authors.initials: J
authors.lastname: Bauer
authors.forename: FranCoise
authors.initials: F
authors.lastname: Livio
mesh_terms: D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001707:Biopsy, Needle / Q000379:methods; D018567:Breast Neoplasms, Male / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D018270:Carcinoma, Ductal, Breast / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D004232:Diuretics / Q000009:adverse effects*; D006467:Hemophilia A / Q000209:etiology* / Q000628:therapy; D006801:Humans; D008297:Male; D008327:Mammography; D008408:Mastectomy / Q000379:methods; D010257:Paraneoplastic Syndromes / Q000209:etiology; D013148:Spironolactone / Q000009:adverse effects*; D013629:Tamoxifen / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D004232:Diuretics; D013629:Tamoxifen; D013148:Spironolactone